Fébuxostat : interactions médicamenteuses

Fébuxostat (Uloric), inhibiteur de la xanthine oxydase, présente 136 interactions documentées dans les notices FDA et les fiches d'information que nous indexons : 10 de niveau majeur, 88 de niveau modéré, 28 de niveau mineur et 10 cas où une notice ne signale aucune interaction significative. Chaque entrée ci-dessous cite la phrase sur laquelle elle repose. Cette page consacrée à un médicament est un point de départ, pas un verdict sur votre situation.

Interactions d'après la notice

Interactions majeures (10)

  • AdénosineantiarythmiqueMajeure

    Use of methylxanthines (e.g., caffeine, aminophylline and theophylline) is not recommended in patients who experience a seizures in association with adenosine injection ( 5.6 ) (notice Adénosine, Mises en garde et précautions)

  • AdrénalinesympathomimétiqueMajeure

    …hormones Diuretics Cardiac glycosides, such as digitalis glycosides Quinidine Drugs potentiating hypokalemic effects of epinephrine • Potassium depleting diuretics • Corticosteroids • Theophylline Epinephrine should not be used to counteract circulatory collapse or hypotension caused by phenothiazines, as a reversal of the pressor effects of epinephrine may result… (notice Adrénaline, Interactions médicamenteuses)

  • Allopurinolinhibiteur de la xanthine oxydaseMajeure

    WARNING: CARDIOVASCULAR DEATH Gout patients with established cardiovascular (CV) disease treated with ULORIC had a higher rate of CV death compared to those treated with allopurinol in a CV outcomes study [see Warnings and Precautions (5.1) ] . (notice Fébuxostat, Mise en garde encadrée)

  • AzathioprineimmunosuppresseurMajeure

    ULORIC is contraindicated in patients being treated with azathioprine or mercaptopurine [see Drug Interactions (7) ] . (notice Fébuxostat, Contre-indications)

  • CiprofloxacinefluoroquinoloneMajeure

    Serious Adverse Reactions with Concomitant Theophylline Serious and fatal reactions have been reported in patients receiving concurrent administration of ciprofloxacin and theophylline. (notice Ciprofloxacine, Mises en garde et précautions)

  • Déférasiroxsupplément de ferMajeure

    Avoid the use of Exjade with CYP1A2 substrate theophylline. (notice Déférasirox, Interactions médicamenteuses)

  • Kétaminedépresseur du SNCMajeure

    Theophylline or Aminophylline : Do not co-administer with KETALAR as concomitant use may lower the seizure threshold ( 7.1 ). (notice Kétamine, Interactions médicamenteuses)

  • MercaptopurineantimétaboliteMajeure

    ULORIC is contraindicated in patients being treated with azathioprine or mercaptopurine [see Drug Interactions (7) ] . (notice Fébuxostat, Contre-indications)

  • RifampicineantibiotiqueMajeure

    Quinine Prevention or Management : Avoid concomitant use Decrease AUC by 75%-85% Telithromycin Decrease AUC by 86% Theophylline Decrease exposure by 20%-40% Effect of Other Drugs on Rifampin Concomitant antacid administration may reduce the absorption of rifampin. (notice Rifampicine, Interactions médicamenteuses)

  • RiociguatvasodilatateurMajeure

    Phosphodiesterase Inhibitors Concomitant administration of Adempas with specific PDE-5 inhibitors (such as sildenafil, tadalafil, or vardenafil) or nonspecific PDE-5 inhibitors (such as dipyridamole or theophylline) is contraindicated [see Dosage and Administration (2.6), Drug Interactions ( 7.1 ) and Clinical Pharmacology ( 12.2 )]. (notice Riociguat, Contre-indications)

Interactions modérées (88)

  • Acide méfénamiqueAINSModérée

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (notice Fébuxostat, Mises en garde et précautions)

  • AclidiniumanticholinergiqueModérée

    Sympathomimetics, Methylxanthines, Steroids In clinical studies, concurrent administration of aclidinium bromide and other drugs commonly used in the treatment of COPD including sympathomimetics (short-acting beta 2 agonists), methylxanthines, and oral and inhaled steroids showed no increases in adverse drug reactions. (notice Aclidinium, Interactions médicamenteuses)

  • AdalimumabimmunosuppresseurModérée

    Upon initiation or discontinuation of Adalimumab-fkjp in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed. (notice Adalimumab, Interactions médicamenteuses)

  • AlbendazoleModérée

    Theophylline: Albendazole induces cytochrome P450 1A in human hepatoma cells; therefore, it is recommended that plasma concentrations of theophylline be monitored during and after treatment. (notice Albendazole, Interactions médicamenteuses)

  • Arformotérolagoniste bêta-adrénergiqueModérée

    Xanthine derivatives, steroids, diuretics, or non-potassium sparing diuretics may potentiate hypokalemia or ECG changes. (notice Arformotérol, Interactions médicamenteuses)

  • AspirineAINSModérée

    Consider use of prophylactic low-dose aspirin therapy in patients with a history of CV disease. (notice Fébuxostat, Mises en garde et précautions)

  • Aspirine et dipyridamoleantiagrégant plaquettaireModérée

    Consider use of prophylactic low-dose aspirin therapy in patients with a history of CV disease. (notice Fébuxostat, Mises en garde et précautions)

  • BupropionantidépresseurModérée

    …also increase the risk of seizure: concomitant use of other medications that lower the seizure threshold (e.g., other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, and systemic corticosteroids), metabolic disorders (e.g., hypoglycemia, hyponatremia, severe hepatic impairment, and hypoxia), or use of illicit drugs (e.g., cocaine)… (notice Bupropion, Mises en garde et précautions)

  • Consider use of prophylactic low-dose aspirin therapy in patients with a history of CV disease. (notice Fébuxostat, Mises en garde et précautions)

  • Consider use of prophylactic low-dose aspirin therapy in patients with a history of CV disease. (notice Fébuxostat, Mises en garde et précautions)

  • ButorphanolopioïdeModérée

    …Interactions It is not known if the effects of Butorphanol Tartrate Injection are altered by concomitant medications that affect hepatic metabolism of drugs (CYP 450 inhibitors or inducers) (e.g., erythromycin, theophylline, etc.), but physicians should be alert to the possibility that a smaller initial dose and longer intervals between doses may be needed. (notice Butorphanol, Interactions médicamenteuses)

  • Cannabidiol (sur ordonnance)anticonvulsivantModérée

    Increases in exposure of certain CYP1A2 substrates (e.g., theophylline, tizanidine) may be observed when concomitantly used with EPIDIOLEX. (notice Cannabidiol (sur ordonnance), Interactions médicamenteuses)

  • CélécoxibAINSModérée

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (notice Fébuxostat, Mises en garde et précautions)

  • CétirizineantihistaminiqueModérée

    There was a small decrease in the clearance of oral cetirizine hydrochloride caused by a 400-mg dose of theophylline; it is possible that larger theophylline doses could have a greater effect [see Clinical Pharmacology ( 12.3 )]. (notice Cétirizine, Interactions médicamenteuses)

  • Cimétidineantihistaminique H2Modérée

    …apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline, and metronidazole, thereby delaying elimination and increasing blood levels of these drugs. (notice Cimétidine, Interactions médicamenteuses)

  • Clarithromycineantibiotique macrolideModérée

    Xanthine Derivatives: Theophylline Use With Caution Theophylline: Clarithromycin use in patients who are receiving theophylline may be associated with an increase of serum theophylline concentrations [see Pharmacokinetics ( 12.3 )] . (notice Clarithromycine, Interactions médicamenteuses)

  • ColchicineModérée

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (notice Fébuxostat, Mises en garde et précautions)

  • Désogestrel et éthinylestradiolcontraceptif oralModérée

    Effects of Combined Hormonal Contraceptives on Other Drugs COCs containing EE may inhibit the metabolism of other compounds (e.g., cyclosporine, prednisolone, theophylline, tizanidine, and voriconazole) and increase their plasma concentrations. (notice Désogestrel et éthinylestradiol, Interactions médicamenteuses)

  • DiclofénacAINSModérée

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (notice Fébuxostat, Mises en garde et précautions)

  • In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (notice Fébuxostat, Mises en garde et précautions)

  • Diclofénamideinhibiteur de l'anhydrase carboniqueModérée

    Drugs that Cause Hypokalemia The risk of hypokalemia is greater with coadministration of KEVEYIS and other drugs that can cause hypokalemia (e.g., loop diuretics, thiazide diuretics, laxatives, antifungals, penicillins, and theophylline) [see Warnings and Precautions (5.3) ] . (notice Diclofénamide, Interactions médicamenteuses)

  • DiflunisalAINSModérée

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (notice Fébuxostat, Mises en garde et précautions)

  • DoxapramModérée

    There may be an interaction between doxapram and aminophylline and between doxapram and theophylline manifested by increased skeletal muscle activity, agitation, and hyperactivity. (notice Doxapram, Interactions médicamenteuses)

  • Drospirénone et éthinylestradiolcontraceptif oralModérée

    …studies, administration of a hormonal contraceptive containing EE did not lead to any increase or only to a weak increase in plasma concentrations of CYP3A4 substrates (e.g., midazolam) while plasma concentrations of CYP2C19 substrates (e.g., omeprazole and voriconazole) and CYP1A2 substrates (e.g., theophylline and tizanidine) can have a weak or moderate increase. (notice Drospirénone et éthinylestradiol, Interactions médicamenteuses)

  • Dutastéride et tamsulosineinhibiteur de la 5-alpha-réductaseModérée

    Tamsulosin Dosage adjustments are not necessary when tamsulosin is administered concomitantly with digoxin or theophylline [see Clinical Pharmacology (12.3) ]. (notice Dutastéride et tamsulosine, Interactions médicamenteuses)

  • Érythromycineantibiotique macrolideModérée

    Drug Interactions Theophylline Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity. (notice Érythromycine, Interactions médicamenteuses)

  • ÉtodolacAINSModérée

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (notice Fébuxostat, Mises en garde et précautions)

  • Effects of CHCs on Other Drugs CHCs containing ethinyl estradiol may inhibit the metabolism of other compounds (e.g., cyclosporine, prednisolone, theophylline, tizanidine, and voriconazole) and increase their plasma concentrations. (notice Étonogestrel et éthinylestradiol, Interactions médicamenteuses)

  • FénoprofèneAINSModérée

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (notice Fébuxostat, Mises en garde et précautions)

  • Fluconazoleantifongique azoléModérée

    (See CLINICAL PHARMACOLOGY: Drug Interaction Studies .) Theophylline Fluconazole increases the serum concentrations of theophylline. (notice Fluconazole, Interactions médicamenteuses)

  • FlurbiprofèneAINSModérée

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (notice Fébuxostat, Mises en garde et précautions)

  • FluvoxamineISRSModérée

    Theophylline: Clearance decreased; reduce theophylline dose by one-third ( 5.8 ). (notice Fluvoxamine, Mises en garde et précautions)

  • Formotérolagoniste bêta-adrénergiqueModérée

    • Xanthine derivatives, steroids, diuretics, or non-potassium sparing diuretics may potentiate hypokalemia or ECG changes. (notice Formotérol, Interactions médicamenteuses)

  • FosphénytoïneanticonvulsivantModérée

    John's wort may vary widely based on preparation. theophylline Drugs that may either increase or decrease phenytoin serum levels Antiepileptic drugs Phenobarbital, valproate sodium, valproic acid 7.2 Drugs Affected by Phenytoin or CEREBYX Table 7 includes commonly occurring drug interactions affected by phenytoin (the active metabolite of CEREBYX). (notice Fosphénytoïne, Interactions médicamenteuses)

  • In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (notice Fébuxostat, Mises en garde et précautions)

  • IbuprofèneAINSModérée

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (notice Fébuxostat, Mises en garde et précautions)

  • In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (notice Fébuxostat, Mises en garde et précautions)

  • IndométacineAINSModérée

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (notice Fébuxostat, Mises en garde et précautions)

  • InfliximabimmunosuppresseurModérée

    Upon initiation or discontinuation of RENFLEXIS in patients being treated with CYP450 substrates with a narrow therapeutic index, monitoring of the effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) is recommended and the individual dose of the drug product may be adjusted as needed. (notice Infliximab, Interactions médicamenteuses)

  • IsoniazideantibiotiqueModérée

    Theophylline A recent study has shown that concomitant administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid. (notice Isoniazide, Interactions médicamenteuses)

  • KétoprofèneAINSModérée

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (notice Fébuxostat, Mises en garde et précautions)

  • KétorolacAINSModérée

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (notice Fébuxostat, Mises en garde et précautions)

  • Lansoprazoleinhibiteur de la pompe à protons (IPP)Modérée

    Theophylline Clinical Impact: Increased clearance of theophylline [see Clinical Pharmacology (12.3) ] . (notice Lansoprazole, Interactions médicamenteuses)

  • LéflunomideimmunosuppresseurModérée

    In patients taking ARAVA, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. (notice Léflunomide, Interactions médicamenteuses)

  • LévocétirizineantihistaminiqueModérée

    There was a small decrease (~16%) in the clearance of cetirizine caused by a 400 mg dose of theophylline. (notice Lévocétirizine, Interactions médicamenteuses)

  • LévofloxacinefluoroquinoloneModérée

    However, concomitant administration of other fluoroquinolones with theophylline has resulted in prolonged elimination half-life, elevated serum theophylline levels, and a subsequent increase in the risk of theophylline-related adverse reactions in the patient population. (notice Lévofloxacine, Interactions médicamenteuses)

  • Lévonorgestrel et éthinylestradiolcontraceptif oralModérée

    Concomitant use with ethinyl estradiol-containing CHCs may increase systemic exposure of other drugs (e.g., cyclosporine, prednisolone, theophylline, tizanidine, and voriconazole). (notice Lévonorgestrel et éthinylestradiol, Interactions médicamenteuses)

  • MéloxicamAINSModérée

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (notice Fébuxostat, Mises en garde et précautions)

  • MéthotrexateimmunosuppresseurModérée

    Effect of XATMEP on Other Drugs Theophylline Methotrexate may decrease the clearance of theophylline. (notice Méthotrexate, Interactions médicamenteuses)

  • MexilétineantiarythmiqueModérée

    Concurrent use of mexiletine and theophylline may lead to increased plasma theophylline levels. (notice Mexilétine, Interactions médicamenteuses)

  • NabumétoneAINSModérée

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (notice Fébuxostat, Mises en garde et précautions)

  • Naltrexone et bupropionantagoniste des opioïdesModérée

    …may cause hypoglycemia concomitant administration of medications that may lower the seizure threshold, including other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, systemic steroids Recommendations for Reducing the Risk of Seizure: Clinical experience with bupropion suggests that the risk of seizure may be minimized by adhering to… (notice Naltrexone et bupropion, Mises en garde et précautions)

  • NaproxèneAINSModérée

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (notice Fébuxostat, Mises en garde et précautions)

  • In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (notice Fébuxostat, Mises en garde et précautions)

  • NéfazodoneantidépresseurModérée

    FEV 1 measurements taken when theophylline and nefazodone were coadministered did not differ from baseline dosage (i.e., when theophylline was administered alone). (notice Néfazodone, Interactions médicamenteuses)

  • Effects of Combined Hormonal Contraceptives on Other Drugs CHCs containing EE may inhibit the metabolism of other compounds (e.g., cyclosporine, prednisolone, theophylline, tizanidine, and voriconazole) and increase their plasma concentrations. (notice Norelgestromine et éthinylestradiol, Interactions médicamenteuses)

  • Norgestimate et éthinylestradiolcontraceptif oralModérée

    Effects of Combined Oral Contraceptives on Other Drugs COCs containing EE may inhibit the metabolism of other compounds (e.g., cyclosporine, prednisolone, theophylline, tizanidine, and voriconazole) and increase their plasma concentrations. (notice Norgestimate et éthinylestradiol, Interactions médicamenteuses)

  • Norgestrel et éthinylestradiolcontraceptif oralModérée

    Effects of Combined Oral Contraceptives on Other Drugs COCs containing EE may inhibit the metabolism of other drugs (e.g., cyclosporine, prednisolone, theophylline, tizanidine, and voriconazole) and increase their plasma concentrations. (notice Norgestrel et éthinylestradiol, Interactions médicamenteuses)

  • OfloxacinefluoroquinoloneModérée

    This may result in a prolonged half-life for some drugs that are also metabolized by this system (e.g., cyclosporine, theophylline/methylxanthines, warfarin) when coadministered with quinolones. (notice Ofloxacine, Interactions médicamenteuses)

  • Consider use of prophylactic low-dose aspirin therapy in patients with a history of CV disease. (notice Fébuxostat, Mises en garde et précautions)

  • OxaprozineAINSModérée

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (notice Fébuxostat, Mises en garde et précautions)

  • In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (notice Fébuxostat, Mises en garde et précautions)

  • PhénytoïneanticonvulsivantModérée

    John’s wort may vary widely based on preparation. , sucralfate, theophylline Drugs that may either increase or decrease phenytoin serum levels Antiepileptic drugs Phenobarbital, valproate sodium Valproate sodium and valproic acid are similar medications. (notice Phénytoïne, Interactions médicamenteuses)

  • PiroxicamAINSModérée

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (notice Fébuxostat, Mises en garde et précautions)

  • PrimaquineantipaludiqueModérée

    Effects of Primaquine on the Pharmacokinetics of Other Drugs CYP1A2 Substrates Published clinical and non-clinical reports indicate primaquine inhibits CYP1A2 enzyme activity and thus may lead to increased exposure of CYP1A2 substrate drugs (e.g., duloxetine, alosetron, theophylline and tizanidine) when co-administered with Primaquine phosphate Tablets. (notice Primaquine, Interactions médicamenteuses)

  • In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (notice Fébuxostat, Mises en garde et précautions)

  • PropylthiouracileantithyroïdienModérée

    Theophylline: Theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid; a reduced dose of theophylline may be needed. (notice Propylthiouracile, Interactions médicamenteuses)

  • QuinineantipaludiqueModérée

    Theophylline or Aminophylline In 20 healthy subjects who received multiple doses of quinine sulfate (648 mg every 8 hours x 7 days) with a single 300 mg oral dose of theophylline, the quinine mean C max and AUC were increased by 13% and 14% respectively. (notice Quinine, Interactions médicamenteuses)

  • RifapentineantibiotiqueModérée

    …Clofibrate Oral Hypoglycemics Sulfonylureas (e.g., glyburide, glipizide) Hormonal Contraceptives/Progestins Ethinyl estradiol, levonorgestrel Immunosuppressants Cyclosporine, tacrolimus Methylxanthines Theophylline Narcotic analgesics Methadone Phosphodiesterase-5 (PDE-5) Inhibitors Sildenafil Thyroid preparations Levothyroxine Tricyclic antidepressants Amitriptyline,… (notice Rifapentine, Interactions médicamenteuses)

  • RitonavirantirétroviralModérée

    Bronchodilator: theophylline ↓ theophylline Increased dosage of theophylline may be required; therapeutic monitoring should be considered. (notice Ritonavir, Interactions médicamenteuses)

  • RosuvastatinestatineModérée

    Febuxostat Prevention or Management: In patients taking febuxostat, do not exceed a dosage of rosuvastatin tablets 20 mg once daily. (notice Rosuvastatine, Interactions médicamenteuses)

  • SalsalateAINSModérée

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (notice Fébuxostat, Mises en garde et précautions)

  • SucralfateModérée

    Drug Interactions Some studies have shown that simultaneous sucralfate administration in healthy volunteers reduced the extent of absorption (bioavailability) of single doses of the following: cimetidine, digoxin, fluoroquinolone antibiotics, ketoconazole, l-thyroxine, phenytoin, quinidine, ranitidine, tetracycline, and theophylline. (notice Sucralfate, Interactions médicamenteuses)

  • SulindacAINSModérée

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (notice Fébuxostat, Mises en garde et précautions)

  • In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (notice Fébuxostat, Mises en garde et précautions)

  • Tadalafilinhibiteur de la PDE5Modérée

    When tadalafil was administered to subjects taking theophylline, a small augmentation (3 beats per minute) of the increase in heart rate associated with theophylline was observed. (notice Tadalafil, Interactions médicamenteuses)

  • TamsulosinealphabloquantModérée

    Digoxin and Theophylline Dosage adjustments are not necessary when a tamsulosin hydrochloride capsule is administered concomitantly with digoxin or theophylline [see Clinical Pharmacology ( 12.3 )] . (notice Tamsulosine, Interactions médicamenteuses)

  • TerbinafineantifongiqueModérée

    The influence of terbinafine on the pharmacokinetics of fluconazole, cotrimoxazole (trimethoprim and sulfamethoxazole), zidovudine or theophylline was not considered to be clinically significant. (notice Terbinafine, Interactions médicamenteuses)

  • TériflunomideimmunosuppresseurModérée

    In patients taking AUBAGIO, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. (notice Tériflunomide, Interactions médicamenteuses)

  • ThéophyllineméthylxanthineModérée

    Therefore, use with caution when coadministering ULORIC with theophylline. (notice Fébuxostat, Interactions médicamenteuses)

  • ThiamazoleantithyroïdienModérée

    Theophylline: Theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid; a reduced dose of theophylline may be needed. (notice Thiamazole, Interactions médicamenteuses)

  • TiotropiumanticholinergiqueModérée

    Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (notice Tiotropium, Interactions médicamenteuses)

  • TocilizumabimmunosuppresseurModérée

    Upon initiation or discontinuation of TOFIDENCE, in patients being treated with these types of medicinal products, perform therapeutic monitoring of effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) and the individual dose of the medicinal product adjusted as needed. (notice Tocilizumab, Interactions médicamenteuses)

  • TolmétineAINSModérée

    In order to prevent gout flares when ULORIC is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended [see Dosage and Administration (2.4) ]. (notice Fébuxostat, Mises en garde et précautions)

  • VaréniclineModérée

    • Effect of Smoking Cessation on Other Drugs: Pharmacokinetics or pharmacodynamics of certain drugs (e.g., theophylline, warfarin, insulin) may be altered, necessitating dose adjustment. (notice Varénicline, Interactions médicamenteuses)

  • Vérapamilinhibiteur calciqueModérée

    Theophylline Verapamil may inhibit the clearance and increase the plasma levels of theophylline. (notice Vérapamil, Interactions médicamenteuses)

  • Zafirlukastantagoniste des récepteurs des leucotriènesModérée

    Coadministration of zafirlukast (20 mg/day) or placebo at steady-state with a single dose of sustained release theophylline preparation (16 mg/kg) in 16 healthy boys and girls (6 through 11 years of age) resulted in no significant differences in the pharmacokinetic parameters of theophylline. (notice Zafirlukast, Précautions)

  • Zileutoninhibiteur du CYP1A2Modérée

    Zileuton increases theophylline levels. (notice Zileuton, Interactions médicamenteuses)

Mentions mineures (28)

  • AcébutololbêtabloquantMineure

    A bronchodilator, such as theophylline or a β2-stimulant, should be made available in advance with instructions concerning its use. (notice Acébutolol, Mises en garde)

  • AminophyllineméthylxanthineMineure

    Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays. (notice Aminophylline, Interactions médicamenteuses)

  • Anagrélidemédicament allongeant l'intervalle QTMineure

    CYP1A2 substrates: AGRYLIN demonstrates limited inhibitory activity towards CYP1A2 in vitro and may alter the exposure of concomitant CYP1A2 substrates (e.g., theophylline, fluvoxamine, ondansetron). (notice Anagrélide, Interactions médicamenteuses)

  • Bénazépril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Mineure

    In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (notice Fébuxostat, Interactions médicamenteuses)

  • In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (notice Fébuxostat, Interactions médicamenteuses)

  • Candésartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Mineure

    In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (notice Fébuxostat, Interactions médicamenteuses)

  • CarbamazépineanticonvulsivantMineure

    Such drugs include the following: Aminophylline, c isplatin, doxorubicin, felbamate, phosphenytoin, methsuximide , phenobarbital, phenytoin, primidone, rifampin and theophylline. (notice Carbamazépine, Interactions médicamenteuses)

  • CidofovirantiviralMineure

    …Probenecid Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine). (notice Cidofovir, Interactions médicamenteuses)

  • Désipramineantidépresseur tricycliqueMineure

    In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (notice Fébuxostat, Interactions médicamenteuses)

  • Énalapril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Mineure

    In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (notice Fébuxostat, Interactions médicamenteuses)

  • Fosinopril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Mineure

    In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (notice Fébuxostat, Interactions médicamenteuses)

  • Hydrochlorothiazidediurétique thiazidiqueMineure

    In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (notice Fébuxostat, Interactions médicamenteuses)

  • IpratropiumanticholinergiqueMineure

    ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

  • Irbésartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Mineure

    In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (notice Fébuxostat, Interactions médicamenteuses)

  • Lisinopril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Mineure

    In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (notice Fébuxostat, Interactions médicamenteuses)

  • Lithiummédicament sérotoninergiqueMineure

    Acetazolamide, Urea, Xanthine Preparations, Alkalinizing Agents Clinical Impact: Concomitant use can lower serum lithium concentrations by increasing urinary lithium excretion. (notice Lithium, Interactions médicamenteuses)

  • Losartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Mineure

    In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (notice Fébuxostat, Interactions médicamenteuses)

  • In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (notice Fébuxostat, Interactions médicamenteuses)

  • Olmésartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Mineure

    In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (notice Fébuxostat, Interactions médicamenteuses)

  • Olmésartan, amlodipine et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Mineure

    In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (notice Fébuxostat, Interactions médicamenteuses)

  • Falsely high readings for theophylline have been reported in an in vitro study, using the Schack and Waxler technique, when therapeutic concentrations of theophylline and probenecid were added to human plasma. (notice Probénécide, Interactions médicamenteuses)

  • Quinapril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Mineure

    In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (notice Fébuxostat, Interactions médicamenteuses)

  • Ropivacaïneanesthésique localMineure

    Possible interactions with drugs known to be metabolized by CYP1A2 via competitive inhibition such as theophylline and imipramine may also occur. (notice Ropivacaïne, Interactions médicamenteuses)

  • Spironolactone et hydrochlorothiazideantagoniste de l'aldostéroneMineure

    In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (notice Fébuxostat, Interactions médicamenteuses)

  • Telmisartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Mineure

    In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (notice Fébuxostat, Interactions médicamenteuses)

  • Triamtérène et hydrochlorothiazidediurétique épargneur de potassiumMineure

    In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (notice Fébuxostat, Interactions médicamenteuses)

  • Valsartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Mineure

    In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (notice Fébuxostat, Interactions médicamenteuses)

  • WarfarineanticoagulantMineure

    In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (notice Fébuxostat, Interactions médicamenteuses)

Aucune interaction significative signalée (10)

  • AlosétronAucune interaction

    The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (notice Alosétron, Interactions médicamenteuses)

  • DofétilideantiarythmiqueAucune interaction

    Other Drugs: In healthy volunteers, amlodipine, phenytoin, glyburide, ranitidine, omeprazole, hormone replacement therapy (a combination of conjugated estrogens and medroxyprogesterone), antacid (aluminum and magnesium hydroxides), and theophylline did not affect the pharmacokinetics of dofetilide. (notice Dofétilide, Interactions médicamenteuses)

  • FamciclovirantiviralAucune interaction

    …Penciclovir No clinically significant alterations in penciclovir pharmacokinetics were observed following single-dose administration of 500 mg famciclovir after pretreatment with multiple doses of allopurinol, cimetidine, theophylline, zidovudine, promethazine, when given shortly after an antacid (magnesium and aluminum hydroxide), or concomitantly with emtricitabine. (notice Famciclovir, Interactions médicamenteuses)

  • Finastérideinhibiteur de la 5-alpha-réductaseAucune interaction

    Compounds that have been tested in man have included antipyrine, digoxin, propranolol, theophylline, and warfarin and no clinically meaningful interactions were found. (notice Finastéride, Interactions médicamenteuses)

  • Montélukastantagoniste des récepteurs des leucotriènesAucune interaction

    No dose adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology… (notice Montélukast, Interactions médicamenteuses)

  • Nizatidineantihistaminique H2Aucune interaction

    Drug Interactions No interactions have been observed between nizatidine and theophylline, chlordiazepoxide, lorazepam, lidocaine, phenytoin, and warfarin. (notice Nizatidine, Interactions médicamenteuses)

  • OlanzapineantipsychotiqueAucune interaction

    Theophylline — Multiple doses of olanzapine did not affect the pharmacokinetics of theophylline or its metabolites. (notice Olanzapine, Interactions médicamenteuses)

  • Olanzapine et fluoxétineantipsychotiqueAucune interaction

    Theophylline — Multiple doses of olanzapine did not affect the pharmacokinetics of theophylline or its metabolites. (notice Olanzapine et fluoxétine, Interactions médicamenteuses)

  • Ropiniroleagoniste de la dopamineAucune interaction

    Theophylline: Administration of theophylline (300 mg twice daily), a substrate of CYP1A2, did not alter the steady-state pharmacokinetics of ropinirole (2 mg 3 times daily) in 12 patients with Parkinson’s disease. (notice Ropinirole, Interactions médicamenteuses)

  • TiagabineanticonvulsivantAucune interaction

    Theophylline : A single 10 mg dose of tiagabine did not affect the pharmacokinetics of theophylline at steady state. (notice Tiagabine, Interactions médicamenteuses)

Vérifiez Fébuxostat avec tout ce que vous prenez. Ajoutez votre liste complète ; toutes les paires sont vérifiées en une fois.

Ouvrir dans le vérificateur

Ceci n'est pas un avis médical. Le niveau de gravité reflète la formulation de la notice, pas votre situation. Une alerte « majeure » peut être courante sous surveillance et une alerte « mineure » peut compter à forte dose. Demandez conseil à un pharmacien.